1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424. https://doi.org/10.3322/caac.21492
2. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF et al (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1151-1210. https://doi.org/10.1016/S0140-6736(17)32152-9
3. Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2018) SEER cancer statistics review, 1975-2018. National Cancer Institute, Bethesda, MD. https://seer.cancer.gov/csr/1975_2018/. Accessed April 2021
4. Devesa SS, Bray F, Vizcaino AP, Parkin DM (2005) International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117:294-299. https://doi.org/10.1002/ijc.21183
5. Oronsky B, Reid TR, Oronsky A, Carter CA (2017) What’s new in SCLC? A review. Neoplasia 19:842-847. https://doi.org/10.1016/j.neo.2017.07.007
6. Bernhardt EB, Jalal SI (2016) Small cell lung cancer. Springer International Publishing, pp 301-322
Bernhardt EB, Jalal SI (2016) Small Cell Lung Cancer. Cancer Treat Res 170:301-22. https://doi.org/10.1007/978-3-319-40389-2_14
7. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 24:4539-4544. https://doi.org/10.1200/JCO.2005.04.4859
8. Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890-895. https://doi.org/10.1200/JCO.1992.10.6.890
9. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624. https://doi.org/10.1056/NEJM199212033272302
10. Lu H, Fang L, Wang X, Cai J, Mao W (2014) A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Mol Clin Oncol 2:805-810. https://doi.org/10.3892/mco.2014.311
11. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A et al (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 18:1116-1125. https://doi.org/10.1016/S1470-2045(17)30318-2
12. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271. https://doi.org/10.1056/NEJM199901283400403
13. Fujii M, Hotta K, Takigawa N, Hisamoto A, Ichihara E, Tabata M, Tanimoto M, Kiura K (2012) Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response. Lung Cancer 78:107-111. https://doi.org/10.1016/j.lungcan.2012.07.001
14. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P (2007) Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev 33:461-473. https://doi.org/10.1016/j.ctrv.2007.03.002
15. Turrisi AT 3rd (1994) Platinum combined with radiation therapy in small cell lung cancer: focusing like a laser beam on crucial issues. Semin Oncol 21:36-42
16. Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF et al (1996) Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 14:806-813. https://doi.org/10.1200/JCO.1996.14.3.806
17. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S et al (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060. https://doi.org/10.1200/JCO.2002.12.071
18. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7-33. https://doi.org/10.3322/caac.21654
19. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220-2229. https://doi.org/10.1056/NEJMoa1809064
20. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929-1939. https://doi.org/10.1016/S0140-6736(19)32222-6
21. Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G et al (2020) Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small-cell lung cancer: the ADRIATIC study. Clin Lung Cancer 21:e84-e8.
22. Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T et al (2014) Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer 14:18. https://doi.org/10.1186/1471-2407-14-18
23. Kalemkerian GP (2016) Small cell lung cancer. Semin Respir Crit Care Med 37:783-796. https://doi.org/10.1055/s-0036-1592116
24. Badzio A, Kurowski K, Karnickamlodkowska H, Jassem J (2004) A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 26:183-188. https://doi.org/10.1016/j.ejcts.2004.04.012
25. Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM Jr, Deming RL, Kozelsky TF, Marks RS, Jett JR, Adjei AA (2009) Prognostic factors differ by tumor stage for small cell lung cancer. Cancer 115:2721-2731. https://doi.org/10.1002/cncr.24314
26. Hermes A, Gatzemeier U, Waschki B, Reck M (2010) Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis. Respir Med 104:1937-1942. https://doi.org/10.1016/j.rmed.2010.07.013
27. Reymen B, Van Loon J, van Baardwijk A, Wanders R, Borger J, Dingemans AM et al (2013) Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer. Int J Radiat Oncol Biol Phys 85:1319-1324. https://doi.org/10.1016/j.ijrobp.2012.10.003
28. Wolf M, Holle R, Hans K, Drings P, Havemann K (1991) Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 63:986-992. https://doi.org/10.1038/bjc.1991.215
29. Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z et al (2010) Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer 67:221-226. https://doi.org/10.1016/j.lungcan.2009.04.006
30. Ball DL, Fisher RJ, Burmeister BH, Poulsen MG, Graham PH, Penniment MG et al (2013) The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol 106:305-311. https://doi.org/10.1016/j.radonc.2012.12.003
31. Karin M, Taugner J, Käsmann L, Eze C, Roengvoraphoj O, Tufman A et al (2020) Association of planning target volume with patient outcome in inoperable stage III NSCLC treated with chemoradiotherapy: a comprehensive single-center analysis. Cancers 12:3035. https://doi.org/10.3390/cancers12103035
32. Koo TR, Moon SH, Lim YJ, Kim JY, Kim Y, Kim TH et al (2014) The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiat Oncol 9:283. https://doi.org/10.1186/s13014-014-0283-6